Pharma Stocks
-
IL0011408896) Faces Pressure Amid Biotech Sector Volatility
UroGen Pharma Ltd stock (ISIN: IL0011408896) trades under scrutiny as investors weigh clinical progress against cash burn in a tough…
Read More » -
Takeda Pharmaceutical (ADR) Stock Steady Amid Pharma Sector Volatility as Investors Eye Pipeline Pro
Takeda Pharmaceutical (ADR) stock (ISIN: US8740602052) holds firm around $17.77, reflecting resilience in a choppy market, with focus shifting to…
Read More » -
ES0157097017) Faces Headwinds Amid Dermatology Pipeline Setbacks
Almirall S.A. stock (ISIN: ES0157097017) trades under pressure as investors digest mixed clinical trial results and broader European pharma sector…
Read More » -
US7739031091) Faces Pressure Amid R&D Surge and Margin Sq
Regeneron Pharmaceuticals Inc stock (ISIN: US7739031091) dropped 3.6% on March 12, 2026, to $746.61, signaling investor concerns over rising costs…
Read More » -
The Bull Case For Daiichi Sankyo Company (TSE:4568) Could Change Following ENHERTU’s Priority Review Success
In March 2026, Daiichi Sankyo and AstraZeneca announced that the U.S. FDA accepted and granted Priority Review to their supplemental…
Read More » -
Verrica Pharmaceuticals Q4 Loss Reignites Debate On Path To Sustainable Profitability
Verrica Pharmaceuticals (VRCA) just closed out FY 2025 with Q4 revenue of US$5.1 million and a basic EPS loss of…
Read More » -
PreMkt 13 Mar 2026: 0503.HK Lansen Pharma HK +40.94% to HK$1.79: targets
0503.HK stock opened pre-market after a sharp intraday move, trading at HK$1.79, a +40.94% rise versus the previous close, on…
Read More » -
Piramal Pharma Ltd Stock Falls to 52-Week Low Amidst Cont…
Recent Price Movement and Market Context The stock has underperformed notably, falling by 6.41% on the day and underperforming its…
Read More » -
Is It Too Late To Consider Ligand Pharmaceuticals (LGND) After A 105% One-Year Surge?
If you are wondering whether Ligand Pharmaceuticals at US$221.24 is still offering value after a big run, you are not…
Read More » -
Assessing Pharma Mar (BME:PHM) Valuation After Zepzelca Milestones And Strong 2025 Growth Update
Pharma Mar (BME:PHM) has drawn fresh attention after its 2025 results update, with management pointing to 27% revenue growth, a…
Read More »